Repurposing alcohol-abuse drug disulfiram for the treatment of KSHV-infected primary effusion lymphoma by activating antiviral innate immunity
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1012957 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Lijie Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hunan International Joint Laboratory of Animal Intestinal Ecology and Health, Laboratory of Animal Nutrition and Human Health, Hunan Provincial Key L…. Hauptthemen laut MEDLINE: Lymphoma, Primary Effusion, Herpesvirus 8, Human, Immunity, Innate, Disulfiram. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Project of China, Shanghai Frontiers Science Center of Cellular Homeostasis and Human Disease (QL), NSFC, Natural Science Foundation for Outstanding Young Scholar of Hunan Province.
Abstract (Originalsprache)
Cancer remains a leading cause of global mortality, characterized by high treatment costs, and generally poor prognoses. Developing new anti-cancer drugs requires substantial investment, extended development timelines, and a high failure rate. Therefore, repurposing existing US Food and Drug Administration (FDA)-approved drugs for other diseases as potential anti-cancer therapies offers a faster and more cost-effective approach. Primary effusion lymphoma (PEL) is an aggressive B-cell malignancy linked to Kaposi’s sarcoma-associated herpesvirus (KSHV) infection. In this study, we identified that disulfiram (DSF), an FDA-approved medication for alcohol dependence, acts as a potent inhibitor of KSHV-positive PEL. DSF suppresses PEL cell proliferation by inducing apoptosis through the activation of innate antiviral immunity. Remarkably, DSF effectively impedes KSHV reactivation and virion production in both PEL and endothelial cells. Inhibition of TANK binding kinase 1 (TBK1) or interferon regulatory factor 3 (IRF3), essential activators of antiviral innate immunity, reverses DSF’s effects on PEL cell survival and KSHV reactivation. Furthermore, DSF treatment significantly hinders the initiation and progression of PEL tumors in a xenograft mouse model, with this effect was notably abolished by TBK1 depletion. Our findings highlighted DSF as a promising therapeutic agent for targeting persistent KSHV infection and treating PEL tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hunan International Joint Laboratory of Animal Intestinal Ecology and Health, Laboratory of Animal Nutrition and Human Health, Hunan Provincial Key Laboratory of Animal Intestinal Function and Regulation, College of Lif…
- Shanghai Institute of Immunology, Department of Immunology and Microbiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shang…
ORCID-Profile: Tingting Li
Förderung
- National Key Research and Development Project of China
- Shanghai Frontiers Science Center of Cellular Homeostasis and Human Disease (QL), NSFC
- Natural Science Foundation for Outstanding Young Scholar of Hunan Province
- Key Project of Education Department of Hunan Province
- Shanghai Science and Technology Commission
- Shanghai Frontiers Science Center of Cellular Homeostasis and Human Disease
- National Natural Science Foundation of China
- Science Fund for Distinguished Young Scholars of Hunan Province
Zitieren
APA
Wang, L., Liu, Z., Xu, Z., Wang, W., Yang, J., Zhang, J., He, S., Liang, Q., & Li, T. (2025). Repurposing alcohol-abuse drug disulfiram for the treatment of KSHV-infected primary effusion lymphoma by activating antiviral innate immunity. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012957
Vancouver
Wang L, Liu Z, Xu Z, Wang W, Yang J, Zhang J, et al. Repurposing alcohol-abuse drug disulfiram for the treatment of KSHV-infected primary effusion lymphoma by activating antiviral innate immunity. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1012957
BibTeX
@article{Wang2025,
author = {Wang, Lijie and Liu, Zhenshan and Xu, Zeyu and Wang, Wenjing and Yang, Jinhong and Zhang, Junjie and He, Shanping and Liang, Qiming and Li, Tingting},
title = {Repurposing alcohol-abuse drug disulfiram for the treatment of KSHV-infected primary effusion lymphoma by activating antiviral innate immunity},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1012957}
}
EUVIMED